Glovista Investments LLC Holds Position in Merck & Co., Inc. (MRK)
Glovista Investments LLC held its position in Merck & Co., Inc. (NYSE:MRK) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,899 shares of the company’s stock at the end of the fourth quarter. Glovista Investments LLC’s holdings in Merck & Co. were worth $406,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. KBC Group NV raised its stake in Merck & Co. by 32.7% in the third quarter. KBC Group NV now owns 1,398,162 shares of the company’s stock valued at $87,259,000 after buying an additional 344,592 shares during the last quarter. GW&K Investment Management LLC raised its stake in Merck & Co. by 6.6% in the third quarter. GW&K Investment Management LLC now owns 369,150 shares of the company’s stock valued at $23,039,000 after buying an additional 22,736 shares during the last quarter. JT Stratford LLC purchased a new stake in Merck & Co. during the fourth quarter valued at approximately $2,394,000. Sumitomo Mitsui Trust Holdings Inc. raised its stake in Merck & Co. by 1.5% in the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 8,099,715 shares of the company’s stock valued at $505,503,000 after buying an additional 120,129 shares during the last quarter. Finally, DAVENPORT & Co LLC raised its stake in Merck & Co. by 13.3% in the third quarter. DAVENPORT & Co LLC now owns 1,871,109 shares of the company’s stock valued at $116,776,000 after buying an additional 219,289 shares during the last quarter. 74.10% of the stock is currently owned by institutional investors and hedge funds.
Shares of Merck & Co., Inc. (NYSE:MRK) traded down 0.86% during midday trading on Friday, hitting $62.01. 7,428,981 shares of the stock were exchanged. The company has a market cap of $170.25 billion, a PE ratio of 43.98 and a beta of 0.79. The firm has a 50-day moving average price of $63.91 and a 200-day moving average price of $62.49. Merck & Co., Inc. has a 12-month low of $53.06 and a 12-month high of $66.80.
Merck & Co. (NYSE:MRK) last issued its quarterly earnings results on Thursday, February 2nd. The company reported $0.89 earnings per share for the quarter, hitting the consensus estimate of $0.89. The company earned $10.10 billion during the quarter, compared to analysts’ expectations of $10.22 billion. Merck & Co. had a net margin of 14.30% and a return on equity of 24.08%. The business’s quarterly revenue was down 1.0% on a year-over-year basis. During the same period last year, the business earned $0.93 EPS. On average, equities analysts predict that Merck & Co., Inc. will post $3.81 EPS for the current year.
The firm also recently declared a quarterly dividend, which was paid on Friday, April 7th. Stockholders of record on Wednesday, March 15th were paid a dividend of $0.47 per share. The ex-dividend date of this dividend was Monday, March 13th. This represents a $1.88 annualized dividend and a dividend yield of 3.01%. Merck & Co.’s dividend payout ratio is currently 92.61%.
TRADEMARK VIOLATION NOTICE: “Glovista Investments LLC Holds Position in Merck & Co., Inc. (MRK)” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/04/21/merck-co-inc-mrk-stake-held-by-glovista-investments-llc-updated-updated.html.
Several analysts recently weighed in on the stock. Cowen and Company reiterated a “market perform” rating and issued a $68.00 target price on shares of Merck & Co. in a report on Tuesday, April 11th. HSBC Holdings plc downgraded shares of Merck & Co. from a “hold” rating to a “reduce” rating in a report on Friday, April 7th. BMO Capital Markets reiterated a “buy” rating and issued a $70.00 target price on shares of Merck & Co. in a report on Tuesday, March 21st. Leerink Swann reiterated a “market perform” rating on shares of Merck & Co. in a report on Monday, March 20th. Finally, Jefferies Group LLC reiterated an “underperform” rating and issued a $52.00 target price (up previously from $50.00) on shares of Merck & Co. in a report on Saturday, March 11th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have issued a buy rating to the company. Merck & Co. presently has a consensus rating of “Hold” and an average price target of $67.74.
In other news, EVP Adam H. Schechter sold 53,850 shares of the firm’s stock in a transaction that occurred on Monday, April 3rd. The shares were sold at an average price of $63.48, for a total transaction of $3,418,398.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Thomas R. Cech sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, February 3rd. The stock was sold at an average price of $63.42, for a total transaction of $317,100.00. Following the transaction, the director now directly owns 5,100 shares of the company’s stock, valued at $323,442. The disclosure for this sale can be found here. Insiders have sold a total of 160,809 shares of company stock valued at $10,261,846 over the last ninety days. Company insiders own 0.05% of the company’s stock.
About Merck & Co.
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Stock Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related stocks with our FREE daily email newsletter.